Get the Stockscreener App
6.59
0.90%
-0.06
After Hours:
6.59
Exagen Inc stock is traded at $6.59, with a volume of 397.51K.
It is down -0.90% in the last 24 hours and up +49.77% over the past month.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
See More
Previous Close:
$6.65
Open:
$6.65
24h Volume:
397.51K
Relative Volume:
1.03
Market Cap:
$159.21M
Revenue:
$68.38M
Net Income/Loss:
$-20.17M
P/E Ratio:
-7.4556
EPS:
-0.8839
Net Cash Flow:
$-14.13M
1W Performance:
+41.11%
1M Performance:
+49.77%
6M Performance:
+87.75%
1Y Performance:
-26.04%
1-Day Range:
$6.46
$6.76
1-Week Range:
$4.3801
$7.10
52-Week Range:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
6.59 | 106.30M | 68.38M | -20.17M | -14.13M | -0.8839 |
TMO
Thermo Fisher Scientific Inc
|
580.02 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.98 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
590.00 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
141.34 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
399.70 | 36.45B | 3.77B | 449.25M | 240.68M | 7.8556 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | B. Riley Securities | Buy |
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
Exagen Inc. to Participate in Upcoming Investor Conference - The Manila Times
Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exagen Inc (XGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XGN|Exagen Inc|Price:4.390|Chg%:-0.290 - TradingKey
Exagen Inc (XGN) Institutional Confidence - TradingKey
Exagen Inc (XGN) Balance Sheet - TradingKey
Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exagen Inc (XGN) Income Statement - TradingKey
TradingKey - TradingKey
XGN|Exagen Inc|Price:4.680|Chg%:-0.270 - TradingKey
Exagen Inc (XGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exagen Inc (XGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exagen nears break-even with strong revenue gro... - Pluang
Exagen: A Small Diagnostics Company Approaching An Inflection Point (NASDAQ:XGN) - Seeking Alpha
Exagen stock stabilizes as autoimmune testing revenue grows and losses narrow - Ad-hoc-news.de
New Exagen study finds variability in myositis antibody detection methods - Traders Union
Exagen schedules 8:30 a.m. call to review second-quarter results - Stock Titan
ETFs Investing in Exagen, Inc. Stocks - TradingView
Exagen (XGN) Q1 2026 Earnings: EPS Beat Fails to Lift Stock, Revenue Concerns LingerTech Earnings Analysis - dars.gov.et
Exagen Inc. (XGN) Q1 2026 Earnings: Narrower Loss Beats Street Estimates, Yet Shares DeclineFinal Results - dars.gov.et
Exagen Inc focuses on autoimmune diagnostics as investors watch strategy - Ad Hoc News
Exagen Company Profile & Introduction - Moomoo
Exagen Inc. (XGN) Faces Selling Pressure, Testing Key Support at $4.31MFI Divergence - dars.gov.et
XGNExagen Inc Volatility & Greeks - Finviz
Exagen Inc. (XGN) Edges Higher as Stock Consolidates Near Key Support LevelNAAIM Leverage - dars.gov.et
Price to earnings forward of Exagen, Inc. – LS:A2PRXT - TradingView
Enterprise value to EBIT forward of Exagen Inc. – NASDAQ:XGN - TradingView
A2PRXT Forecast — Price Target — Prediction for 2027 - TradingView
Exagen Inc. (XGN) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ResponseSpecial Dividend Alert - dars.gov.et
Price to book forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to EBIT forward of Exagen, Inc. – GETTEX:E08A - TradingView
Enterprise value to EBITDA forward of Exagen Inc. – NASDAQ:XGN - TradingView
Price to sales forward of Exagen Inc. – NASDAQ:XGN - TradingView
Price to sales forward of Exagen, Inc. – GETTEX:E08A - TradingView
Enterprise value to revenue forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to revenue forward of Exagen Inc. – BOATS:XGN - TradingView
Exagen, Inc. Actuals & Estimates (NASDAQ:XGN) - TradingView
Exagen sets dates for second-quarter results, shares watched around Nasdaq listing - ad-hoc-news.de
E08A Forecast — Price Target — Prediction for 2027 - TradingView
XGN Forecast — Price Target — Prediction for 2027 - TradingView
XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rat - GuruFocus
XGN Q1 2026 Earnings: EPS Beat Drives Positive Stock MovementStrong Earnings Momentum - dars.gov.et
Exagen (XGN) Gains Buy Rating with $8 Price Target from Analyst - GuruFocus
Form 4 Exagen Inc For: 24 June By Investing.com - Investing.com Nigeria
Form 4 Exagen Inc For: 22 June By Investing.com - Investing.com Australia
Exagen (XGN) director Scott Kahn receives 37,500 stock options grant - Stock Titan
Exagen (XGN) director granted 37,500 stock options at $4.31 strike - Stock Titan
Exagen (XGN) director Frank Stokes receives 37,500 stock options at $4.31 - Stock Titan
Form 4 Exagen Inc For: 22 June - Investing.com India
Exagen StockSunday background on autoimmune diagnostics specialist - AD HOC NEWS
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exagen Inc Stock (XGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ABALLI JOHN | President and CEO |
Feb 24 '26 |
Sale |
3.61 |
11,430 |
41,262 |
702,997 |
| Black Jeffrey G. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.61 |
1,584 |
5,718 |
267,442 |
| ABALLI JOHN | President and CEO |
Oct 16 '25 |
Sale |
11.82 |
31,787 |
375,598 |
714,427 |
| Black Jeffrey G. | Chief Financial Officer |
Sep 02 '25 |
Sale |
9.79 |
20,466 |
200,362 |
269,026 |
1.13%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):